FDA approves Bristol Myers’ multiple myeloma successor
RegulatoryapprovedZenbexusPositive
AI Analysis
Summary
The FDA has granted accelerated approval to Bristol Myers Squibb's iberdomide (Zenbexus) for patients with relapsed or refractory multiple myeloma. This represents a significant regulatory milestone for the company's multiple myeloma franchise.
Outcome Details
FDA grants accelerated approval for iberdomide (Zenbexus) in relapsed or refractory multiple myeloma
Importance:8/10
Sentiment:
0.95
FDA approvalaccelerated approvalmultiple myelomaoncology
Related Companies
Read the original article
Published by Endpoints News on August 13, 2026 9:19 PM